Sign in
WithdrawnNo phase

xDRIVE in Metastatic Colorectal Cancer

Key facts

Who runs it
First Ascent Biomedical Inc.
Trial code
Status
Withdrawn
Started
15 Sept 2025
Expected to end
30 Jun 2027
Type of study
Observational
Treatments tested
  • Functional precision medicine
Record updated
2 September 2026
Why it stopped
Unable to finalize study agreements

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Participants (men and women) enrolled in internal review board (IRB) 622-00 and meet the following criteria
  • Participants ≥18 years of age with a diagnosis of mCRC who are willing to consent to the study
  • Participants with Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2
  • Participants with measurable disease
  • Participants who need to start SOC cancer-directed systemic therapy
  • Participants able to provide treatment and outcome information from previous lines of therapy
  • Participants who will need a tumor biopsy, excision, or resection as part of their routine clinical care
  • Participants willing to have a blood draw performed for matched normal material
  • Participants who plan to have their first radiographic assessment of their cancer at Mayo Clinic

Who cannot take part

  • Participants with other concurrent cancers besides mCRC which also require ongoing cancer-directed therapy
  • Participants who do not have malignant tissue available or safely accessible or do not have sufficient amount of tissue from anticipated biopsy, excision or resection for testing
  • Participants who do not have measurable disease
  • Participants with insufficient health indicators to undergo therapeutic intervention for mCRC based on treating oncologist's clinical assessment
  • Participants who cannot provide an informed consent

About the trial

What the trial wants to find out

The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC). The primary objective is to assess xDRIVE's accuracy in forecasting clinical benefit from standard-of-care (SOC) therapies, with a target of ≥80% accuracy in 25 participants. Achieving this threshold would provide sufficient statistical power to reject the null hypothesis of ≤50% accuracy.

Read full original descriptionShow less

The secondary goal is to determine the feasibility of utilizing xDRIVE for timely treatment recommendations. Success will be defined by the ability to provide recommendations within four weeks for at least 64% of patients, ensuring clinical applicability.

Additionally, the study includes an exploratory objective to examine oncologists' perspectives on integrating xDRIVE into clinical decision-making. This will be achieved through a post-hoc survey assessing physician experiences with the precision oncology platform.

The group in the trial

  • Metastatic colorectal cancer patients

    Participants with mCRC who need clinical tumor biopsy or resection and need to start systemic therapy for measurable disease.

    Treatment: Functional precision medicine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Feasibility Study to Evaluate a Precision Oncology Platform (xDRIVE) in Participants With Advanced Colorectal Cancer
Record updated
2 September 2026